Company: BIVIW
Filing Date: 2025-07-22
Form Type: S-1/A
Source: 0001520138-25-000216
Chunk: 114

Company: BIOVIE INC.
Filing Date: 2025-07-22
Form: S-1/A
Chunk 114
---
 Officer are primarily based on her 35 years of accounting and finance experience both as a CFO and as a CPA in major global
accounting and consultancy firms.

Dr. Joseph M. Palumbo has served as our
Chief Medical Officer (“CMO”) since 2021. Formerly he served as the CMO at Zynerba Pharmaceuticals from July 2019 to October
2021, responsible for clinical operations, development, regulatory, and medical affairs. Prior to his time at Zynerba, Dr. Palumbo held
senior worldwide governance roles at Mitsubishi Tanabe Pharma in both the United States and Japan from April 2012 to June 2019, where
he led medical science and translational research across multiple therapeutic areas, and guided successful registrational programs for
Radicava® (edaravone) for the treatment of Amyotrophic Lateral Sclerosis. From April 2003 to March 2012, Dr. Palumbo was Global Head
and Franchise Medical Leader for Psychiatry, and the Interim Head of Global Neuroscience at Johnson & Johnson, where he led the medical
teams who achieved successful global registrations for Risperdal® (risperidone); Concerta® (methylphenidate HCL); and Invega®
(paliperidone). He was Head of Psychiatry and Neurology at Pharmanet for from April 2002 to April 2003. Dr Palumbo previously held industry
positions in European Pharma with Sanofi-Synthelabo from April 1999 to April 2002, Biotech at Cephalon, from April 1997 to April 1998,
and from July 1989 to April 2002, he held senior leadership and hospital administration roles at prestigious academic research institutions
including Yale, Cornell, and the University of Pennsylvania. He holds a Bachelor of Arts at the University of Pennsylvania and received
his Doctor of Medicine at the George Washington University School of Medicine. He was a Biological Sciences Training Program Fellow of
the National Institutes of Health and Chief Resident for the Abraham Ribicoff Clinical Neuroscience Research Unit at Yale University.
Dr Palumbo has received Board Certification in Psychiatry and Addiction Psychiatry.

<div align='center'>60</div>

Dr. Palumbo’s qualifications to serve as
our CMO is based on the decades and depth of experiences in the roles he has served in his medical profession and commercial experience
in the healthcare industry and biopharma industries.

Mr. Jim Lang, Chairman of the Board